- Lobbying
- Lobbying by Cauthen Forbes & Williams on behalf of Merck
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeff Forbes | Staff Director, Senate Finance Committee Chief of Staff, Senator Max Baucus Deputy Asst, Special Asst, Deputy Director EOP |
Libby Greer | Chief of Staff, Rep. Allen Boyd |
Zachary Williams | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues related to Part D Medicare and issues related to the drug industry; issues related to vaccines; issues related to PCORI; issues related to ASP+6 and 340B; issues related to the Prescription Drug User Fee Act; issues related to comparative effectiveness; issues related to the Independent Payment Advisory Board; issues related to trade negotiations; PNTR with Russia; issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit, issues related to corporate tax reform..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate